title: Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.
abstract: It has been observed cannabinoid CB1 receptor signalling and the levels of endocannabinoid ligands significantly increased in the basal ganglia and cerebrospinal fluids of Parkinson's disease (PD) patients. These evidences suggest that the blocking of cannabinoid CB1 receptors might be beneficial to improve movement disorders as a sign of PD. In this study, a dose-response study of the effects of intrastriatal injection of a cannabinoid CB1 receptor antagonist, AM251 and agonist, ACPA, on movement activity was performed by measuring the catalepsy of reserpinized and non-PD (normal) rats with bar test. Also the effect of co-administration the most effective dose of AM251 and several doses of ACPA were assessed. AM251 decreases the reserpine induced catalepsy in dose dependent manner and ACPA causes catalepsy in normal rats in dose dependant manner as well. AM251 significantly reverse the cataleptic effect in all three groups (1, 10, 100 ng/rat) that received ACPA. These results support this theory that cannabinoid CB1 receptor antagonists might be useful to alleviate movement disorder in PD. Also continuance of ACPA induced catalepsy in rats after AM251 injection can indicate that other neurotransmitters or receptors interfere in ACPA induced catalepsy. Based on the present finding there is an incomplete overlapping between cannabinoid CB1 receptor agonist and antagonist effects.
authors: Department of Physiology, School of Medicine & Physiology Research Center, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran.
authors: Hadi Fathi
authors: HF
authors: Moghaddam
authors: Mohammad Javad
authors: MJ
authors: Khodayar
authors: Seyed Mohammad Zarei
authors: SM
authors: Abarghouei
authors: Mehdi Shafiee
authors: MS
authors: Ardestani
keywords: ACPA; AM251; Cannabinoid CB1 receptor; Catalepsy; Parkinson’s disease; Reserpine; Striatum
references: Pharmacol Biochem Behav. 1995 May;51(1):3-7
references: 7617730
references: Neuroscience. 1998 Mar;83(2):393-411
references: 9460749
references: Curr Opin Pharmacol. 2003 Feb;3(1):54-61
references: 12550742
references: Life Sci. 1999;65(6-7):703-13
references: 10462071
references: Handb Exp Pharmacol. 2005;(168):479-507
references: 16596785
references: Pharmacol Biochem Behav. 1998 Feb;59(2):347-52
references: 9476980
references: Res Commun Chem Pathol Pharmacol. 1972 Jan;3(1):29-35
references: 5030706
references: Neuropharmacology. 2001 Jun;40(7):918-26
references: 11378162
references: Brain Res. 1995 Oct 2;694(1-2):223-32
references: 8974649
references: Pharmacol Biochem Behav. 2000 Nov;67(3):567-73
references: 11164087
references: J Neurosci. 2002 Aug 15;22(16):6900-7
references: 12177188
references: Prog Neurobiol. 2000 Sep;62(1):63-88
references: 10821982
references: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
references: 10318961
references: Eur J Neurosci. 2001 Dec;14(11):1827-32
references: 11860478
references: Mov Disord. 2002 Nov;17(6):1180-7
references: 12465055
references: Pharmacol Biochem Behav. 1999 Jan;62(1):75-80
references: 9972848
references: Braz J Med Biol Res. 2005 Dec;38(12):1867-72
references: 16302101
references: Psychopharmacologia. 1970 Aug 19;18(1):82-93
references: 5535578
references: Life Sci. 1998;62(4):351-63
references: 9450507
references: Clin Neuropharmacol. 2004 May-Jun;27(3):108-10
references: 15190231
references: Pharmacol Rev. 1986 Mar;38(1):1-20
references: 3520605
references: Nature. 1957 Nov 30;180(4596):1200
references: 13483658
references: Life Sci. 1996;58(15):1249-57
references: 8614278
references: Br J Pharmacol. 1996 Aug;118(8):2199-205
references: 8864562
references: Br J Pharmacol. 1996 Aug;118(8):2053-8
references: 8864542
references: Brain Res Mol Brain Res. 1999 Apr 6;67(1):148-57
references: 10101241
references: Neurosci Lett. 1998 Jun 5;248(3):171-4
references: 9654336
references: Brain Res. 1991 May 3;547(2):267-74
references: 1909204
references: Neurobiol Dis. 2004 Jul;16(2):377-85
references: 15193294
references: Brain Res. 1998 May 18;793(1-2):7-11
references: 9630477
references: Ann Neurol. 2005 May;57(5):777-9
references: 15852389
references: Neurosci Lett. 1996 Mar 8;206(1):21-4
references: 8848272
references: Eur J Pharmacol. 1996 Jan 25;296(2):169-72
references: 8838453
references: Science. 1999 Jan 15;283(5400):401-4
references: 9888857
references: Toxicol Appl Pharmacol. 1997 Feb;142(2):278-87
references: 9070350
references: Eur J Biochem. 1995 Aug 15;232(1):54-61
references: 7556170
references: Neuroscience. 1992;46(4):959-71
references: 1531866
references: J Neurochem. 1993 Nov;61(5):1705-12
references: 7901331
references: Drug Alcohol Depend. 1996 Nov;42(3):155-66
references: 8912798
references: FEBS Lett. 1994 Aug 22;350(2-3):240-4
references: 8070571
references: Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):293-6
references: 18764909
references: Pharmacol Biochem Behav. 2002 Nov;73(4):911-9
references: 12213538
references: J Neurosci. 1997 Jul 15;17(14):5327-33
references: 9204917
references: J Neurosci. 1995 Oct;15(10):6552-61
references: 7472417
references: Life Sci. 2000;66(6):485-94
references: 10794065
references: Eur J Pharmacol. 1996 Jul 18;308(2):161-4
references: 8840127
references: Synapse. 1998 Jan;28(1):27-32
references: 9414015
references: Neuropharmacology. 1991 Mar;30(3):237-44
references: 1649415
references: Recept Channels. 1993;1(2):121-34
references: 8081716
references: Ann N Y Acad Sci. 1998 Nov 16;860:475-9
references: 9928344
references: Synapse. 1998 Oct;30(2):221-6
references: 9723792
references: Neuropharmacology. 2010 Feb;58(2):551-8
references: 19654014
references: J Biol Chem. 1995 Feb 24;270(8):3726-31
references: 7876112
references: Proc Natl Acad Sci U S A. 1992 May 1;89(9):3825-9
references: 1315042
references: Ann Neurol. 2000 Apr;47(4 Suppl 1):S105-12; discussion S112-4
references: 10762137
references: Pharmacol Rev. 1986 Jun;38(2):151-78
references: 3529128
references: Neuroscience. 1992;48(3):655-68
references: 1376455
references: J Neurochem. 1991 Nov;57(5):1769-73
references: 1681035
references: Brain Res. 2010 Feb 26;1316:153-62
references: 20026090
references: J Neurosci. 1991 Feb;11(2):563-83
references: 1992016
references: Brain Res. 2004 Jan 23;996(2):237-45
references: 14697501
references: Neuropharmacology. 1987 Sep;26(9):1431-40
references: 3670563
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
references: 7724569
references: FASEB J. 2000 Jul;14(10):1432-8
references: 10877836
references: Sci Aging Knowledge Environ. 2002 Jul 24;2002(29):re3
references: 14602998
references: Prog Neurobiol. 1999 Jul;58(4):315-48
references: 10368032
references: Science. 1970 Aug 7;169(3945):611-2
references: 4987683
references: J Neurochem. 2003 May;85(4):1018-25
references: 12716433
references: Annu Rev Pharmacol Toxicol. 1995;35:607-34
references: 7598509